{"id":980888,"date":"2026-07-13T07:03:14","date_gmt":"2026-07-13T11:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-alixorexton-demonstrated-sustained-improvement-in-wakefulness-in-adults-with-narcolepsy-type-1-and-type-2-in-long-term-extension-study-interim-analysis\/"},"modified":"2026-07-13T07:03:14","modified_gmt":"2026-07-13T11:03:14","slug":"alkermes-alixorexton-demonstrated-sustained-improvement-in-wakefulness-in-adults-with-narcolepsy-type-1-and-type-2-in-long-term-extension-study-interim-analysis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alkermes-alixorexton-demonstrated-sustained-improvement-in-wakefulness-in-adults-with-narcolepsy-type-1-and-type-2-in-long-term-extension-study-interim-analysis\/","title":{"rendered":"Alkermes\u2019 Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis"},"content":{"rendered":"

<\/p>\n

Alkermes\u2019 Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis<\/b><\/p>\n

\n\u2014 First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2 \u2014<\/i><\/p>\n

\u2014 Improvements in Patient-Reported Cognition and Fatigue Were Also Sustained \u2014<\/i><\/p>\n

\u2014 Alixorexton Was Generally Well Tolerated at All Doses Tested \u2014<\/i><\/p>\n

DUBLIN–(BUSINESS WIRE<\/a>)–Alkermes plc<\/a> (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1<\/sup> on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approximately nine months after the first dose for participants treated with alixorexton in the randomized double-blind period of the Vibrance-1 and Vibrance-2 phase 2 studies. Alixorexton also demonstrated sustained and clinically meaningful improvement from baseline across patient-reported outcomes (PROs) evaluating cognition and fatigue at week 24. Alixorexton was generally safe and well tolerated at all doses tested. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, NT2 and idiopathic hypersomnia (IH).<\/p>\n

\n\u201cFor people living with narcolepsy, symptom burden extends beyond excessive daytime sleepiness and can affect cognitive function and fatigue. It is exciting to see clinically meaningful improvements sustained across these important measures in this analysis of the long-term extension study of alixorexton in patients with narcolepsy type 1 and type 2. The consistency of the data in up to nine months of treatment provides further evidence that alixorexton, across a range of doses, has the potential to address important aspects of disease burden of narcolepsy regardless of narcolepsy type 1 or type 2 diagnosis,\u201d said Yves Dauvilliers, M.D., Ph.D., Professor of Neurology and Physiology, and Director of the Sleep-Wake Disorders Center at the University of Montpellier, France, and Coordinator of the French National Reference Center for Rare Diseases dedicated to narcolepsy and hypersomnias.<\/p>\n

\nThis ongoing open-label extension study is designed to evaluate the long-term safety, tolerability and durability of treatment effect of alixorexton. This interim analysis reflects safety and tolerability data as of the May 12, 2026 data cutoff and efficacy measures collected at week 24 of the LTE for participants who enrolled in the LTE after completing Vibrance-1 (NT1) or Vibrance-2 (NT2), reflecting treatment with alixorexton for up to nine months. The LTE remains ongoing and is open for enrollment for participants who complete ongoing phase 2 and phase 3 studies of alixorexton.<\/p>\n

Narcolepsy Type 1<\/b><\/p>\n